Male Contraception: The Unmet Need
Why a Reversible Male Method Has Eluded Medicine for 60 Years
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- No reversible pharmacological male method is FDA-approved as of 2026; the only male options are condoms, vasectomy, and withdrawal
Reference only. Not medical advice.
What can go wrong
There is no approved reversible pharmacological male method, so the practical risk today is reliance on condoms, withdrawal, or partner methods. Investigational hormonal methods carry the side-effect profiles of androgen-progestin therapy (acne, mood changes, weight gain, altered lipids/HDL, libido changes); non-hormonal candidates remain mostly preclinical or early-phase with limited human safety data.
This is something to take to a clinician. The Atlas can tell you what is known about male contraception: the unmet need in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Since the female combined oral contraceptive arrived in 1960, the male side has produced no new reversible, reversible pharmacological method. The barriers are biological, regulatory, and commercial. Surveys repeatedly find substantial male interest - studies across multiple countries have reported that roughly half or more of men would consider a new male method - yet the pipeline has stalled for decades over a safety/risk-tolerance double standard and a lack of commercial sponsors.
Sixty years after the female pill, men still have two real choices: a barrier or a knife.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
The fundamental asymmetry: female contraception interrupts a single dominant follicle and one ovulation per cycle, a system already built around cyclic suppression. Male contraception must shut down continuous spermatogenesis - a 64-72 day production line generating tens of millions of sperm daily - to the point of azoospermia or severe oligozoospermia (commonly defined in trials as under ~1 million sperm/mL) to be reliable. Achieving that suppression in essentially all men, reversibly, without unacceptable side effects, is the core scientific problem.
The double standard that keeps killing trials
Male contraceptive trials have been paused or criticized over side effects - mood changes, acne, libido shifts, weight gain - that are commonplace on approved female methods. Critics argue the risk-benefit calculus is skewed because men do not bear pregnancy risk, so regulators and sponsors apply a near-zero-harm bar. Advocates counter that any method must still be safe, but that the asymmetry has slowed progress for decades.
What people get wrong
Often saidMen aren't interested in taking responsibility for contraception
ActuallyMultiple multi-country surveys report ~50% or more of men would try a new male method, and many couples want to share the burden; lack of options, not lack of demand, is the bottleneck.
Often saidA male pill is just around the corner
ActuallyIt has been 'a few years away' since the 1970s. As of 2026 the lead candidates (NES/T gel, oral DMAU/MNTDC, non-hormonal YCT-529) are still in early-to-mid clinical trials; none is near market.
Often saidIt's hard because men make too many sperm to stop
ActuallyVolume is part of it, but the harder problems are achieving suppression in nearly all men, full reversibility, and clearing a near-zero side-effect regulatory bar with no commercial sponsor to pay for large trials.
Who profits, and who pushes back
Reproductive-health regulators (general stance)
A contraceptive for a healthy person who is not at medical risk from the condition being prevented must clear an unusually high safety bar.
How we got here
The female pill's 1960 launch was expected to be followed by a male equivalent within a decade. Instead, WHO-coordinated hormonal trials ran through the 1980s-2000s, repeatedly proving efficacy but stalling on side effects, reversibility concerns, and - critically - the withdrawal of pharmaceutical industry sponsorship in the 1990s-2000s. Most current work is funded by NICHD, the Population Council, the Bill & Melinda Gates Foundation, and the nonprofit Male Contraceptive Initiative rather than by major pharma.
- 1960Female combined oral contraceptive approved (US)
- 1970s-90sWHO coordinates international hormonal male contraception research
- 1990, 1996WHO multicenter testosterone-enanthate azoospermia/oligozoospermia efficacy studies published (Lancet)
- 2008-2011Large CONRAD/WHO testosterone-undecanoate + norethisterone trial run
- 2016Behre et al. publish the halted injectable trial in JCEM; double-standard debate erupts
- 2018-2024NES/T transdermal gel advances to Phase 2b; oral DMAU/MNTDC and non-hormonal YCT-529 enter early trials
What we do not know
- Will any reversible pharmacological method reach market in the 2020s-2030s?
- Can the regulatory safety bar be calibrated to the genuine risk profile without a double standard?
- Who will commercialize a male method if major pharma stays out?
At a glance
- Last new reversible method
- None since female pill (1960) - male side still condom/vasectomy/withdrawal
- Sperm output
- ~1,000+ sperm per second; tens to hundreds of millions per ejaculate
- Egg output
- ~1 mature ovum per ~28-day cycle
- Reported male willingness
- ~50%+ in several multi-country surveys
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Male Contraception: The Unmet Need. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Heinemann et al., Hum Reprod - multinational male attitudes survey2005
Across 9 countries, a majority of surveyed men expressed willingness to use a hormonal male method, undercutting the 'men won't use it' assumption
Behre et al., JCEM (WHO/CONRAD injectable trial)2016
Demonstrated high contraceptive efficacy but was halted early by safety committees over mood and other side effects - the case study in the double-standard debate